The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Key Points
AbbVie's third-quarter results exceeded Wall Street's expectations.
Sales from the pharmaceutical company's three top drugs are soaring.
- 10 stocks we like better than AbbVie ›
Pharmaceutical stocks have been on fire this year. The iShares U.S. Pharmaceuticals ETF (NYSEMKT: IHE), which tracks 43 drugmakers, is up almost 29% year to date and 11% over the past month.
There are lots of great stocks in this sector. But one that investors should be watching closely right now is AbbVie (NYSE: ABBV). The company is focused on drugs that treat a range of diseases in the areas of immunology, rheumatology, gastroenterology, dermatology, and oncology, among others.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
The company released its quarterly results on Oct. 31, and they exceeded Wall Street's forecasts. Sales climbed 9.1% to $15.78 billion, which was significantly higher than the $15.59 billion expected. The company posted earnings of $1.86 per share, 11 cents above the $1.77 expected.
AbbVie has a strong stable of top-performing drugs. Sales of Skyrizi, an immunology drug that treats conditions like psoriasis and arthritis, rose a whopping 46.8% to $4.7 billion during the quarter. Sales of Rinvoq, a similar immunology drug, climbed 35.3% to $2.18 billion. And Humira, which is used to treat plaque psoriasis, brought revenue of $993 million, up 55.4% from a year ago.
Image source: Getty Images.
Management said it believes Rinvoq will hit $11 billion in annual revenue by 2027, and Skyrizi will reach the $20 billion mark. AbbVie's current stable of best-selling drugs is impressive, while it continues to expand its pipeline with acquisitions. This is a hot stock in a hot sector well worth watching.
Should you invest $1,000 in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $540,587!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,118,210!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 1, 2025
Matthew Benjamin has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.
Recommended Articles
